| P50 | author | Morenike Oluwatoyin Folayan | Q57906947 |
| | Alash'le Abimiku | Q69526753 |
| | Sophia Osawe | Q114414831 |
| P2093 | author name string | Florita Durueke | |
| | Bali Nanmak | |
| | Chuks Okonkwo | |
| | Evaezi Okporoko | |
| | Godwin Godo-Odemijie | |
| | Wika Gofwen | |
| P2860 | cites work | Challenges of establishing a Community Advisory Board (CAB) in a low-income, low-resource setting: experiences from Bagamoyo, Tanzania | Q21245521 |
| | Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial | Q28972526 |
| | Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand | Q29547531 |
| | Development of a prospective cohort of HIV Exposed Sero-Negative (HESN) individuals in Jos Nigeria | Q30151894 |
| | Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine | Q30578618 |
| | How ethical is your clinical trial? | Q34044823 |
| | 'I heard about this study on the radio': using community radio to strengthen Good Participatory Practice in HIV prevention trials | Q34116294 |
| | Understanding the supports of and challenges to community engagement in the CTSAs | Q35185396 |
| | Evaluating community engagement in global health research: the need for metrics | Q35679041 |
| | Towards a Science of Community Stakeholder Engagement in Biomedical HIV Prevention Trials: An Embedded Four-Country Case Study | Q35752023 |
| | Ethical challenges for the "outside" researcher in community-based participatory research | Q35946455 |
| | Safety and efficacy of the HVTN 503/Phambili study of a clade-B-based HIV-1 vaccine in South Africa: a double-blind, randomised, placebo-controlled test-of-concept phase 2b study | Q36158727 |
| | Beginning community engagement at a busy biomedical research programme: experiences from the KEMRI CGMRC-Wellcome Trust Research Programme, Kilifi, Kenya | Q37192415 |
| | Advancing community stakeholder engagement in biomedical HIV prevention trials: principles, practices and evidence | Q38244981 |
| | Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand | Q39358681 |
| | Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. | Q45938142 |
| | Community engagement and investment in biomedical HIV prevention research for youth: rationale, challenges, and approaches | Q46775692 |
| | The complexity of circulating HIV type 1 strains in Oyo state, Nigeria. | Q50622318 |
| | Research priorities during infectious disease emergencies in West Africa. | Q51784690 |
| | It is not just about "the trial": the critical role of effective engagement and participatory practices for moving the HIV research field forward | Q58595669 |
| | Stakeholder engagement to inform HIV clinical trials: a systematic review of the evidence | Q58595713 |
| | Community-based participatory research: implications for public health funding | Q73740186 |
| | Building and maintaining trust in a community-based participatory research partnership | Q81461906 |
| | Integrating social theory into public health practice | Q81590745 |
| | Community engagement in research: frameworks for education and peer review | Q84432283 |
| | Considerations for community engagement when conducting clinical trials during infectious disease emergencies in West Africa | Q93168422 |
| P921 | main subject | Nigeria | Q1033 |
| | stakeholder participation | Q2930198 |
| P304 | page(s) | 179 | |
| P577 | publication date | 2019-12-05 | |
| P1433 | published in | The Pan African medical journal | Q27722840 |
| P1476 | title | Community stakeholder engagement during a vaccine demonstration project in Nigeria: lessons on implementation of the good participatory practice guidelines | |
| P478 | volume | 34 | |